Payment overview · 2025
General Payments
$274.19
13 reported records · 9 companies
Healthcare provider profile · identity verified
Mary Beth Miller, MD
Allopathic & Osteopathic Physicians|Family Medicine · THE VILLAGES, FL · NPI 1851331821
Verified facts
What the public records show
CMS Open Payments records show Mary Beth Miller, MD received $274.19 in general payments during 2025 across 13 reported records.
Exact Sciences Corporation accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Wegovy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $105.75 | 38.6% | 5 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $30.08 | 11.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $26.31 | 9.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.09 | 8.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.26 | 7.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.30 | 7.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.79 | 6.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.36 | 5.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.25 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $274.19 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $81.89 | 4 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $30.08 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 158 |
| Levothyroxine Sodium | Levothyroxine Sodium | 256 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 115 |
| Omeprazole | Omeprazole | 232 | 114 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 109 |
| Lisinopril | Lisinopril | 186 | 80 |
| Losartan Potassium | Losartan Potassium | 180 | 89 |
| Gabapentin | Gabapentin | 164 | 72 |
| Methylprednisolone | Methylprednisolone | 145 | 118 |
| Trazodone Hcl | Trazodone Hcl | 130 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 40 |
| Alprazolam | Alprazolam | 98 | 38 |
| Metformin Hcl | Metformin Hcl | 95 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 29 |
| Simvastatin | Simvastatin | 81 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 45 |
| Azithromycin | Azithromycin | 73 | 61 |
| Famotidine | Famotidine | 69 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 31 |
| Tramadol Hcl | Tramadol Hcl | 65 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 30 |
| Alendronate Sodium | Alendronate Sodium | 59 | 22 |
| Jardiance | Empagliflozin | 59 | 18 |
| Potassium Chloride | Potassium Chloride | 53 | 27 |
| Allopurinol | Allopurinol | 52 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 22 |
| Sertraline Hcl | Sertraline Hcl | 52 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 15 |
| Prednisone | Prednisone | 48 | 30 |
| Montelukast Sodium | Montelukast Sodium | 45 | 25 |
| Synthroid | Levothyroxine Sodium | 45 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 19 |
| Carvedilol | Carvedilol | 42 | 21 |
| Eliquis | Apixaban | 42 | 16 |
| Furosemide | Furosemide | 42 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 20 |
| Atenolol | Atenolol | 39 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 15 |
| Donepezil Hcl | Donepezil Hcl | 38 | 14 |
| Memantine Hcl | Memantine Hcl | 37 | 12 |
| Ozempic | Semaglutide | 37 | 12 |
| Estradiol | Estradiol | 36 | 20 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 14 |
| Meloxicam | Meloxicam | 32 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 29 |
| Ondansetron Odt | Ondansetron | 30 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | 16 |
| Metformin Hcl Er | Metformin Hcl | 29 | 13 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | 14 |
| Fluconazole | Fluconazole | 27 | 16 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 17 |
| Valsartan | Valsartan | 25 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 14 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $274.19 · 13 records | Exact Sciences Corporation | BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Heplisav-B, JOURNAVX, LEQVIO, MOUNJARO, OTEZLA, REPATHA, The Cologuard Plus Collection Kit, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error